{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:58:29Z","timestamp":1777946309937,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,28]],"date-time":"2009-04-28T00:00:00Z","timestamp":1240876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,28]],"date-time":"2009-04-28T00:00:00Z","timestamp":1240876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemostasis"],"abstract":"<jats:p>The antithrombotic effect of a thromboxane A&lt;sub&gt;2&lt;\/sub&gt; receptor antagonist (HN-11501:5-[2-(4-chlorophenylsulfonylamino)-ethyl]-2-thienyloxy-acetic acid) alone and in combination with other antithrombotic agents has been studied in an experimental thrombosis model in which laser lesions are used to induce a defined thrombosis in rat mesenteric venules. The thromboxane receptor antagonist showed a significant and dose-dependent antithrombotic effect if given orally. The strongest additive thrombosis-inhibiting effect was observed after oral administration of HN-11501 at a dose of 2.5 mg\/kg together with an intravenous infusion of 1 \u00b5g\/kg\/h of a prostacyclin analogue (cicaprost). An additive antithrombotic effect was also observed after oral application of 2.5 mg\/kg of HN-11501 and intravenous injection of 0.2 mg\/kg of a low molecular weight heparin (Fraxiparine\u00ae). The combination of 2.5 mg\/kg of HN-11501 orally with an intravenous injection of 0.1 mg\/kg molsidomine also had a significant additive effect. No significant additive effect was observed when 2.5 mg\/kg of HN-11501 and 10 mg\/kg of acetylsalicylic acid were orally administered simultaneously.<\/jats:p>","DOI":"10.1159\/000216342","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T10:05:34Z","timestamp":1240999534000},"page":"322-329","source":"Crossref","is-referenced-by-count":0,"title":["Individual and Combined Effects of a Thromboxane Receptor Antagonist and Different Antithrombotic Agents in a Rat Microcirculatory Thrombosis Model"],"prefix":"10.1159","author":[{"given":"J.","family":"Giedrojc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.K.","family":"Breddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,28]]},"container-title":["Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:42:14Z","timestamp":1777740134000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216342","archive":["Portico"],"relation":{},"ISSN":["0301-0147","1423-0038"],"issn-type":[{"value":"0301-0147","type":"print"},{"value":"1423-0038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,28]]}}}